A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine

The clinical use of endogenous neuropeptides has historically been limited due to pharmacokinetic issues, including plasma stability and blood-brain barrier permeability. In this study, we show that the rapidly metabolized Leu-enkephalin (LENK) neuropeptide may become pharmacologically efficient owi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jiao, Lepetre-Mouelhi, Sinda, Gautier, Anne, Mura, Simona, Cailleau, Catherine, Coudore, François, Hamon, Michel, Couvreur, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374102/
https://www.ncbi.nlm.nih.gov/pubmed/30788432
http://dx.doi.org/10.1126/sciadv.aau5148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374102/
https://www.ncbi.nlm.nih.gov/pubmed/30788432
http://dx.doi.org/10.1126/sciadv.aau5148

Ejemplares similares